Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.
BACKGROUND
Hepatitis C virus (HCV) causes significant morbidity and mortality in injecting drug users (IDU) worldwide. HCV vaccine candidates have shown promise for reducing the infectivity of acute infection and averting chronic infection, yet the impact of varying levels of vaccine efficacy and vaccine delivery strategies on the HCV epidemic in IDU have not been explored.


METHODS
We utilized extensive data on injecting behavior collected in the UFO Study of young IDU in San Francisco to construct a stochastic individual-based model that reflects heterogeneous injecting risk behavior, historical HCV trends, and existing information on viral dynamics and vaccine characteristics.


RESULTS
Our modeled HCV rate closely paralleled observed HCV incidence in San Francisco, with estimated incidence of 59% per person year (ppy) early in the epidemic, and 27% ppy after risk reduction was introduced. Chronic HCV infection, the clinically relevant state of HCV infection that leads to liver disease and hepatocellular cancer, was estimated at 22% ppy (± 3%) early in the epidemic and 14% ppy (± 2%) after risk reduction was introduced. We considered several scenarios, and highlight that a vaccine with 50% to 80% efficacy targeted to high-risk or sero-negative IDU at a high vaccination rate could further reduce chronic HCV incidence in IDU to 2-7% ppy 30 years after its introduction.


CONCLUSIONS
Our results underscore the importance of further efforts to develop both HCV vaccines and optimal systems of delivery to IDU populations.
Hahn
Judith A
JA
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143-0811, USA. judy.hahn@ucsf.edu
Wylie
Dennis
D
Dill
Jesse
J
Sanchez
Maria S
MS
Lloyd-Smith
James O
JO
Page-Shafer
Kimberly
K
Getz
Wayne M
WM
D003198:Computer Simulation; D016174:Hepacivirus / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D015995:Prevalence; D012495:San Francisco / Q000453:epidemiology; D013269:Stochastic Processes; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000523:psychology / Q000821:virology; D014761:Viral Hepatitis Vaccines
D014761:Viral Hepatitis Vaccines
Drug Alcohol Depend. 2007 Nov;91 Suppl 1:S64-72
17276018
J Infect Dis. 2002 Dec 1;186(11):1558-64
12447730
Med Decis Making. 2001 Sep-Oct;21(5):357-67
11575485
Drug Alcohol Depend. 2007 Nov;91 Suppl 1:S39-47
17466464
J Clin Microbiol. 2008 Feb;46(2):499-506
18032621
J Hepatol. 2006 Oct;45(4):529-38
16879891
Math Biosci. 2004 Mar-Apr;188:29-45
14766092
Int J Epidemiol. 2007 Apr;36(2):396-405
17218325
Int J Drug Policy. 2007 Oct;18(5):341-51
17854721
J Urban Health. 2007 May;84(3):436-54
17356901
N Engl J Med. 1994 Mar 17;330(11):784-6
8107747
J Infect Dis. 2007 Jun 1;195(11):1556-9
17471423
Gastroenterology. 2007 Apr;132(4):1626-8
17418169
Hepatology. 2006 Nov;44(5):1139-45
17058216
J Med Virol. 2005 Dec;77(4):509-18
16254983
AIDS. 1998 May 7;12(7):801-11
9619813
Clin Infect Dis. 2004 Nov 15;39(10):1540-3
15546094
Lancet. 2002 Apr 27;359(9316):1478-83
11988247
J Public Health Med. 2003 Jun;25(2):165-70
12848409
AIDS. 2007 Sep 12;21(14):1923-32
17721100
J Clin Virol. 2008 Feb;41(2):129-33
18069058
J Viral Hepat. 2006 Aug;13(8):560-70
16901287
Vaccine. 2005 Feb 18;23(13):1549-58
15694507
J Viral Hepat. 2008 Mar;15(3):229-36
18233994
Int J Epidemiol. 2003 Oct;32(5):708-14
14559736
Clin Infect Dis. 2008 Jun 15;46(12):1852-8
18462109
Drug Alcohol Depend. 2008 Jan 11;93(1-2):148-54
17977668
Eur J Epidemiol. 1999 Jan;15(1):5-10
10098989
Nat Med. 2008 Jan;14(1):25-7
18064037
Hepatology. 2001 Jul;34(1):180-7
11431749
Proc Biol Sci. 2007 Dec 7;274(1628):2925-33
17878137
J Viral Hepat. 2008 Apr;15(4):279-92
18208496
Nat Med. 2006 Feb;12(2):190-7
16462801
J Viral Hepat. 2006 Jan;13(1):34-41
16364080
J Urban Health. 2005 Mar;82(1):151-61
15746385
AIDS. 2005 Oct;19 Suppl 3:S20-5
16251819
Nature. 2005 Aug 18;436(7053):961-6
16107836
Transfusion. 2005 Jun;45(6):994-1002
15934999
Mt Sinai J Med. 2000 Oct-Nov;67(5-6):423-8
11064493
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10149-54
15220475
Transfusion. 2003 Oct;43(10):1433-41
14507276
J Urban Health. 2007 Jan;84(1):99-115
17200799
Am J Public Health. 2001 Jan;91(1):46-7
11189823
Transfus Clin Biol. 2001 Jun;8(3):200-6
11499958
J Viral Hepat. 2007 Jun;14(6):413-8
17501762
Am J Public Health. 2003 Jun;93(6):919-23
12773355
Hepatology. 2007 Sep;46(3):666-71
17657818
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S336-8
15768344
Eur Addict Res. 2002 Jan;8(1):45-9
11818693
Am J Public Health. 1996 May;86(5):655-61
8629715